HC restrains generic pharma firms from making, selling patent drug of Novartis

Updated: few hours ago

New Delhi, Nov 2 (PTI) The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major Novartis AG.

The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech, generic pharma firms making or selling Valsartan and Sacubitril.

Novartis, being the patentee, has been selling Valsartan and Sacubitril tablets in India under the brand “Vymada” since 2016.